Current Report Filing (8-k)
January 09 2023 - 08:51AM
Edgar (US Regulatory)
0001782107 false 0001782107 2023-01-09
2023-01-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (Date of earliest event reported):
January 9, 2023
Blue Water Vaccines Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-41294 |
|
83-2262816 |
(State
or other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS
Employer
Identification No.) |
201 E. Fifth Street,
Suite
1900
Cincinnati,
Ohio |
|
45202 |
(Address of Principal Executive
Offices) |
|
(Zip
Code) |
Registrant’s telephone number, including area code: (513)
620-4101
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each
Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which
Registered |
Common Stock, par value $0.00001 per share |
|
BWV |
|
The
Nasdaq Stock Market LLC |
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On January 9, 2023, Blue Water Vaccines, Inc. (the “Company”)
issued a press release announcing that on January 11, 2023 the
Company will present at the Biotech Showcase 2023 in San Francisco,
California, happening during the 41st Annual J.P. Morgan Healthcare
Conference. During the presentation, management will provide a
corporate overview, recent milestones and execution, and company
pipeline updates..
The full text of the press release is furnished as Exhibit 99.1 to
this Form 8-K and is incorporated by reference in this Item
7.01.
The foregoing (including Exhibit 99.1) is being furnished pursuant
to Item 7.01 and will not be deemed to be filed for purposes of
Section 18 of the Securities and Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise be subject to the liabilities of
that section, nor will it be deemed to be incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the
Exchange Act.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
Blue Water
Vaccines Inc. |
|
|
Date: January
9, 2023 |
By: |
/s/ Joseph Hernandez |
|
|
Joseph Hernandez |
|
|
Chief Executive
Officer |
2
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Apr 2023 to May 2023
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From May 2022 to May 2023